Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters.89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the pricing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
